BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up After Analyst Upgrade

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) gapped up before the market opened on Thursday after Zacks Research upgraded the stock to a hold rating. The stock had previously closed at $19.38, but opened at $20.31. BlossomHill Therapeutics shares last traded at $20.05, with a volume of 15,940 shares trading hands.

Other analysts have also recently issued reports about the stock. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. Guggenheim started coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Leerink Partners initiated coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Finally, JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Insiders Place Their Bets

In other news, General Counsel Vincent Liptak acquired 2,200 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, with a total value of $35,200.00. Following the completion of the purchase, the general counsel directly owned 111,412 shares in the company, valued at approximately $1,782,592. This trade represents a 2.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John P. Schmid bought 6,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $96,000.00. Following the transaction, the director directly owned 6,000 shares of the company’s stock, valued at approximately $96,000. This trade represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

BlossomHill Therapeutics News Roundup

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a bullish outlook: The firm initiated research coverage and assigned a “Buy” rating with a $35 price target, implying meaningful upside from recent trading levels. Its estimates also project narrowing losses, from $3.71 per share in fiscal 2026 to $2.99 in fiscal 2027. HC Wainwright coverage
• Positive Sentiment: Broader institutional attention: Guggenheim, Leerink Partners, JPMorgan Chase and Lifesci Capital have also initiated or announced research coverage on BLSM. Expanded analyst coverage can improve investor awareness and potentially increase trading liquidity. Guggenheim coverage
• Positive Sentiment: Upcoming investor presentations: BlossomHill plans to present at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference, giving investors an opportunity to receive updates on its oncology pipeline and development strategy. BlossomHill investor presentations
• Neutral Sentiment: Zacks upgraded BLSM to “Hold.” The change indicates a more neutral stance rather than a strong sell signal, but it may temper the optimism created by the new “Buy” coverage. Zacks rating change
• Negative Sentiment: BlossomHill remains loss-making. HC Wainwright forecasts additional quarterly losses through 2027, including an estimated $3.71-per-share loss for fiscal 2026. The stock therefore remains dependent on clinical progress, future financing and eventual commercialization prospects.

BlossomHill Therapeutics Price Performance

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.